Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mediator subunit MED4 enforces metastatic dormancy in breast cancer.

Nature cell biology·2026
Same author

DPY30 Is an Epigenetic Decoupler Linking Replication Stress to Immunoediting in Pancreatic Cancer.

Cancer research·2026
Same author

Viral mimicry may help explain immunogenic cell death.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

GFER Represents a Target for Dual Disruption of Redox Homeostasis and Reactivation of the Immune Response in Pancreatic Adenocarcinoma.

Cancer research·2025
Same author

KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer.

Cancer research·2025
Same author

Telescopes, telomeres and turning points.

Nature cancer·2025

Related Experiment Video

Updated: Jun 18, 2026

A Preclinical Murine Model of Hepatic Metastases
06:51

A Preclinical Murine Model of Hepatic Metastases

Published on: September 27, 2014

28.7K

Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model.

Yonghong Liu1, Jincheng Han1, Wen-Hao Hsu1

  • 1Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Cancer Discovery
|September 30, 2024
PubMed
Summary

Combining KRAS inhibitors with immunotherapy agents can overcome the immunosuppressive tumor microenvironment in pancreatic cancer (PDAC). This approach led to significant tumor reduction and extended survival in preclinical models.

More Related Videos

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.1K
Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

12.6K

Related Experiment Videos

Last Updated: Jun 18, 2026

A Preclinical Murine Model of Hepatic Metastases
06:51

A Preclinical Murine Model of Hepatic Metastases

Published on: September 27, 2014

28.7K
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.1K
Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

12.6K

Area of Science:

  • Oncology
  • Immunology
  • Cancer Biology

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunosuppressive tumor microenvironment.
  • KRAS mutations are common drivers in PDAC, and their inhibition is an area of active research.
  • Immunotherapy (IO) agents have shown promise but face challenges in PDAC due to the tumor microenvironment.

Purpose of the Study:

  • To investigate the efficacy of combining KRAS inhibitors with IO agents in PDAC.
  • To assess the impact of this combination on the tumor microenvironment and anti-tumor immunity.

Main Methods:

  • Utilized clinically available KRAS inhibitors and IO agents.
  • Employed an autochthonous PDAC model to evaluate therapeutic effects.
  • Analyzed changes in the tumor microenvironment and immune cell populations.

Main Results:

  • Combined KRAS inhibition and IO agents alleviated the immunosuppressive tumor microenvironment in PDAC.
  • Significant tumor regression was observed in the preclinical model.
  • Prolonged survival was achieved in animals treated with the combination therapy.

Conclusions:

  • Combining KRAS inhibition with IO agents represents a promising strategy for PDAC treatment.
  • Targeting multiple components of the immunity cycle alongside KRAS inhibition may enhance therapeutic outcomes.
  • This combination warrants further clinical investigation for combating PDAC.